[ET Net News Agency, 27 January 2021] Macquarie Research lifted its target price for
Alibaba Health Information Technology (00241) to HK$31.5 from HK$24 and maintained its
"buy" rating.
The research house sees the gross merchandise value (GMV) advantage for AliHealth
continuing. Despite its lower ARPU versus JD Health (06618), AliHealth has the advantage
of efficiently penetrating its parent's user pool with a lower user acquisition cost.
Macquarie also estimated that AliHealth's adjusted OPM will improve from 2.2% in FY2020
to 8.3% in FY2023, while it expects JD Health's adjusted OPM will improve from 4.5% in
2019 to 7.5% in 2022. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00241 ALI HEALTH
Nominal 
2.610 -0.040 (-1.509%) Research Report
27/01/2021 17:09
{I-bank focus}Macquarie lifts Ali Health (00241) to HK$31.5
| Remark: | Real time quote last updated: 19/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |